A multicentre prospective, observational, longitudinal cohort study in adult patients with suspected upper or lower respiratory infection (URTI/LRTI) to identify a spectrum of biomarkers in exhaled breath to discriminate participants with bacterial RTI from participants without.
Identification of chemical biomarkers in exhaled breath that potentially discriminates participants with bacterial RTI from participants without.
Additional endpoints explored will be variations of the chemical spectrum from all participants using a portable GC-IMS device (Breathspec) stratified by confounding factors, such as (but not limited to) gender, age, antibiotic therapy and smoking status.
Director of EMERGE, Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine
Diagnostics devices play an important part in the clinical assessment of a patient’s health and treatment. The purpose of the study is the evaluation of a new diagnostic platform developed by LumiraDx. The evaluation is focused around various biomarkers useful in the emergency settings.
Collection of venous and capillary blood samples for the evaluation of new diagnostic devices for cardiovascular conditions
DASH is a randomised clinical trial investigating a treatment to reverse the effects of blood-thinning medications.
TARGET CTCA is a joint venture between EMERGE and the cardiology research team aiming to recruit patients with suspected ACS across NHS Lothian and NHS Greater Glasgow and Clyde. The study aims to recruit 2270 participants. For further information, please contact the EMERGE team.